BLS Pharmaceuticals Limited · ASX:BLS
BLS Pharmaceuticals — Q4 FY2026 Earnings Presentation
16 slides from BLS Pharmaceuticals's earnings presentation, Jul 30, 2026
Slide 1: BLS Q4 FY2026 Results Investor Presentation
Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180 30 July 2026 BLS Q4 FY2026 RESULTS INVESTOR PRESENTATION BLS Pharmaceuticals Limited (ASX: BLS) (“BLS” or “the Company”) is pleased to release an updated investor presentation for its inve
Slide 2: Breathe Life Sciences (BLS) overview
Breathe Life Sciences (BLS) is a wholly owned subsidiary of BLS Pharmaceuticals Limited and a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA. Established in 2018, BLS has developed an international pharmaceutic
Slide 3: Q4 FY2026 Results
Q4 FY2026 Results ASX: BLS | July 2026
Slide 4: Market Opportunity
MARKET OPPORTUNITY A profitable, cash flow positive international pharmaceutical manufacturer serving high-growth regulated markets. International Pharmaceutical Platform Australia • Europe • United Kingdom • LATAM High Barriers to Entry BLS’ multi-jurisdictional licence stack, GMP know- how, scale
Slide 5: Another Record BLS Result
ANOTHER RECORD BLS RESULT Unaudited Q4 FY2026 Results FY26 REVENUE RECORD REVENUE Q4 FY26 CASH RECEIPTS $75m $22.5m $20.7m Top end of upgraded guidance of 5% above Q4 FY26 In line with Q3FY26 $65-$75m FY26 ADJ. EBITDA CASH ON HAND (30 JUNE 2026) CASH FLOW $19m $13.3m +$6.3m 190% on FY25 Up from $8.5
Slide 6: Executing Our Growth Strategy
EXECUTING OUR GROWTH STRATEGY European Expansion: Germany Driven by strong Australian demand FY26 REVENUE $50m ADREXpharma supply and accelerating international agreement signed May 2026, $25m minimum commitment in Year 1 $75m Record Result commercial execution First LATAM Market Entry Dr Watson® ca
Slide 7: Cash Flow Positive
CASH FLOW POSITIVE Record operating cash flow of $6.3m generated during Q4 FY26, reflecting strong cash conversion and disciplined working capital management Cash receipts remained strong at $20.7m, reflecting normal payment timing associated with larger $20.7m international supply agreements and cu
Slide 8: Inventory Investment Supports Revenue Growth
INVENTORY INVESTMENT SUPPORTS REVENUE GROWTH Growing Revenue & Inventory INVENTORY BUILD AND REVENUE Inventory increased from $3.6m to $18.0m during FY26 to support accelerating customer demand and international expansion $22.5m Revenue continued to outpace inventory $21.3m investment, reaching a re
Slide 9: Building Global Relationships
BUILDING GLOBAL RELATIONSHIPS Our commercial platform continues to attract pharmaceutical, manufacturing and healthcare partners across regulated international markets. UK Expansion Manufacturing Government-Backed UK BLS Manufacturing EUROPE Site $50m European Supply Agreement BLS is Aurora’s Austra
Slide 10: Scaling GMP Infrastructure
SCALING GMP INFRASTRUCTURE Building a fully integrated international GMP UNITED KINGDOM pharmaceutical manufacturing platform Scotland GMP Facility EUROPE Commercial Distribution and market access AUSTRALIA Manufacture Distribute Commercialise Existing GMP Hub GLOBAL EXPANSION STRATEGY Fully integra
Slide 11: Soaring Valuations & Investment in Psychedelics & Medicinal Cannabis
SOARING VALUATIONS & INVESTMENT IN PSYCHEDELICS & MEDICINAL CANNABIS Large pharmaceutical companies are increasingly investing in next generation mental health therapies. Recent transactions include: →US$3.8bn (2026) Eli Lilly proposed acquisition of AtaiBeckley → US$1.2bn (2025) AbbVie acquisition
Slide 12: Capturing Significant Margin
CAPTURING SIGNIFICANT MARGIN BLS PHARMACEUTICALS Raw Active PHARMACEAUTICAL WHOLESALE / Pharmacy / Prescribing Patient Materials Pharmaceutical MANUFACTURING DISTRIBUTION Dispensary Physician (Cultivators of Mushrooms, Ingredients (API) Cannabis) Suppliers, Ingredient Licenced Licenced Authorised Do
Slide 13: Integrated Pharmaceutical Manufacturing Platform
INTEGRATED PHARMACEUTICAL MANUFACTURING PLATFORM BLS PHARMACEUTICALS Integrated Pharmaceutical Manufacturing Platform • Licensed by TGA, QLD Health and ODC • GMP-certified manufacturing capability • Importer/exporter of medicinal cannabis, psilocybin, MDMA PHARMACEAUTICAL WHOLESALE / MANUFACTURING D
Slide 14: Board and Management Team
BOARD AND MANAGEMENT TEAM Anthony Ho Samuel Watson Jason Hine Edward Myer Guy Robertson Paul Mitchell Independent Managing Executive Non-Executive BLS Company CFO Australia Non-executive Chair Director & CEO Director & COO Director Secretary Experienced ASX Founder of Breathe Life Former GM Over a d
Slide 15: Corporate Structure
CORPORATE STRUCTURE Capital Structure BLS Share Price Performance (12 Months) Share price A$0.825 Shares on issue 230.0m $1.20 Options & performance rights 14.5m $1.00 Market capitalisation A$190m $0.80 Drawn debt (as at 30 June) A$1.7m $0.60 Cash (as at 30 June) A$13.3m $0.40 Enterprise Value A$178
Slide 16: Contact
Contact BLS Pharmaceuticals Limited NWR Communications Sam Watson Melissa Tempra Chief Executive Officer Media & Investor Relations hello@breathelifesciences.com melissa@nwrcommunications.com.au ASX: BLS | July 2026
BLS Pharmaceuticals — Q4 FY2026 Earnings Presentation on 6ix